The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer
The FDA declined to approve a new lung-cancer drug from Summit Therapeutics.
On Sunday, the Food and Drug Administration declined to approve a new lung-cancer drug, saying the biotech company developing the therapy needs to prove the drug can help people live longer.
In 2022, Summit Therapeutics licensed ivonescimab from Akeso, a Chinese biotech, paying up to $5 billion for the rights to the drug in the U.S., Canada, Europe and Japan.
Summit's stock (SMMT) plunged 13.9% in premarket trade on Monday, while Hong Kong-listed shares of Akeso (HK:9926) were down 22.1%.
The company is trying to get the FDA to approve ivonescimab in combination with chemotherapy for certain patients with metastatic non-small-cell lung cancer. Ivonescimab targets two important proteins: PD-1 and VEGF. Drug developers believe that targeting both proteins will yield a better, potentially more durable response.
The Phase 3 trial, called HARMONi, found that the drug demonstrated an improvement in progression-free survival. But the FDA said it wants to see a statistically significant improvement in overall survival, not a "positive trend" toward overall survival or a post-hoc analysis.
"The HARMONi filing was always at risk: the study did not demonstrate a statistically significant overall survival benefit at its prespecified final analysis, despite FDA having guided this as necessary for approval," Leerink Partners analyst Daina Graybosch told investors. "We expect a modestly negative reaction in Summit."
Ivonescimab, which is already approved in China, is one of the most closely watched cancer drugs in development after a separate study showed the therapy produced better outcomes in lung-cancer patients when tested against Merck's Keytruda.
In the U.S., Summit has bet big on ivonescimab's potential. The company is testing the drug in several cancers, including colorectal cancer and renal cell carcinoma. It's also involved in numerous studies with other drugmakers testing ivonescimab alongside different cancer treatments. AstraZeneca (UK:AZN) recently made a $2 billion equity investment in Summit.
Summit's stock is down 19.2% so far this year, while the State Street SPDR S&P Biotech Exchange-Traded Fund XBI has gained 23.9%.
-Jaimy Lee
Comments